Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.35 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 7/20 | 0.32 |
| ▸ | CDK1 | P06493 | 6/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | DPYD | Q12882 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16753032 | 0.84 | DPYD (0.31) | DPYD | |
| SCHEMBL25860 | 0.80 | PDPK1 (0.53) | PNPPDPK1GDACDK2CDK1 | |
| SCHEMBL29384383 | 0.80 | PDPK1 (0.53) | PNPPDPK1GDACDK2CDK1 | |
| Adenine SCHEMBL28176496 | 0.79 | PI4KA (0.52) | PNPPDPK1GDACDK2DPYD | |
| SCHEMBL13296 | 0.69 | DPYD (0.59) | DPYD | |
| SCHEMBL1982409 | 0.69 | PDPK1 (0.51) | PNPPDPK1GDACDK2CDK1 | |
| SCHEMBL2402087 | 0.69 | PDPK1 (0.51) | PDPK1GDAMGMTCDK2CDK1 | |
| SCHEMBL28144662 | 0.67 | PDPK1 (0.46) | PNPPDPK1GDAMGMTCDK2 | |
| SCHEMBL28313559 | 0.67 | ADORA2A (0.47) | ADORA2AADORA1 | |
| 2,6-Diaminopurine SCHEMBL1064907 | 0.67 | PDPK1 (0.60) | PNPPDPK1GDAMGMTCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363587-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117597112-A | Extracellular vesicles loaded with biomolecules | 鉴识生物系统有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2023278406-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-9745584-B2 | Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4 | CURNA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20150152426-A1 | TREATMENT OF PAR4 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO PAR4 | CURNA, INC. | 2015-06-04 | — | — | US | disclosed |